0.00
100.00%
-32.48
After Hours:
32.48
32.48
+
Cymabay Therapeutics Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $32.49 pivot point. If it approaches the $32.45 support level, significant changes may occur.
Previous Close:
$32.48
Open:
$0
24h Volume:
0
Market Cap:
$3.73B
Revenue:
-
Net Income/Loss:
$-105.37M
P/E Ratio:
0.00
EPS:
-0.88
Net Cash Flow:
$-72.98M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Cymabay Therapeutics Inc Stock (CBAY) Company Profile
Name
Cymabay Therapeutics Inc
Sector
Industry
Phone
510-293-8800
Address
7999 Gateway Boulevard, Suite 130, Newark, CA
Cymabay Therapeutics Inc Stock (CBAY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-13-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
Aug-14-23 | Initiated | UBS | Buy |
Aug-11-23 | Initiated | Guggenheim | Buy |
Apr-05-23 | Initiated | William Blair | Outperform |
Mar-09-23 | Initiated | BTIG Research | Buy |
Apr-11-22 | Resumed | Cantor Fitzgerald | Overweight |
Aug-04-20 | Reiterated | H.C. Wainwright | Buy |
Jul-31-20 | Initiated | Piper Sandler | Overweight |
May-26-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
May-12-20 | Upgrade | Evercore ISI | In-line → Outperform |
May-12-20 | Upgrade | ROTH Capital | Neutral → Buy |
May-12-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-12-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
May-12-20 | Upgrade | Stifel | Hold → Buy |
Mar-13-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Mar-13-20 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-26-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Nov-26-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
Nov-26-19 | Downgrade | ROTH Capital | Buy → Neutral |
Nov-26-19 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
Nov-25-19 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-25-19 | Downgrade | Stifel | Buy → Hold |
Nov-25-19 | Downgrade | SunTrust | Buy → Hold |
Jun-25-19 | Initiated | Stifel | Buy |
Jun-12-19 | Upgrade | Raymond James | Outperform → Strong Buy |
May-14-19 | Initiated | Citigroup | Buy |
View All
Cymabay Therapeutics Inc Stock (CBAY) Latest News
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
Benzinga
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
Zacks Investment Research
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
Benzinga
Cymabay Therapeutics Inc Stock (CBAY) Financials Data
Cymabay Therapeutics Inc (CBAY) Net Income 2024
CBAY net income (TTM) was -$105.37 million for the quarter ending December 31, 2023, a +0.60% increase year-over-year.
Cymabay Therapeutics Inc (CBAY) Cash Flow 2024
CBAY recorded a free cash flow (TTM) of -$72.98 million for the quarter ending December 31, 2023, a +13.36% increase year-over-year.
Cymabay Therapeutics Inc (CBAY) Earnings per Share 2024
CBAY earnings per share (TTM) was -$0.99 for the quarter ending December 31, 2023, a +18.18% growth year-over-year.
About Cymabay Therapeutics Inc
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications. It has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Cap:
|
Volume (24h):